HHS Secretary Price encourages states to use ACA waivers for reinsurance, high-risk pools

While supporting the current proposal to repeal and replace the Affordable Care Act (ACA), HHS Secretary Tom Price, MD, encouraged states to submit more “innovation waivers” as allowed under the ACA to form their own reinsurance programs and fund pools to cover high-cost patients.

In a letter sent to governors across the country, Price said the goal is provide more flexibility at the state level, in accordance with President Donald Trump’s executive order to reduce the “regulatory burdens” under the ACA.

To achieve this, Price didn’t suggest changing the ACA, but rather encouraged states to make greater use Section 1332 of the law allowing for proposals for “State Innovation Waivers” to adapt some of the ACA’s requirements.

“To receive approval, the state must demonstrate that a proposed waiver will provide access to quality health care that is at least as comprehensive and affordable as would be provided without the waiver, will provide coverage to at least a comparable number of residents of the state as would be provided coverage without a waiver, and will not increase the federal deficit,” Price wrote.

He specifically mentioned Alaska’s waiver to extend a state-run reinsurance program, which had been supported by the American Hospital Association and former Healthcare.gov CEO Kevin Counihan. The state legislature had approved the $55 million reinsurance fund in June 2016 after several years of large premium hikes in a state with some of the highest health care costs in the nation. The subsidies are due to sunset after two years.

Alaska’s waiver asks for a $51.6 million in federal funds to support the program in future years. Price said other states can follow their lead, asking for funds for a reinsurance program to lower premiums or fund a state-run high-risk pool, an idea which Price supported as a member of Congress.

“If a state's plan under its waiver proposal is approved, a state may be able to receive pass-through funding to help offset a portion of the costs for the high-risk pool/state-operated reinsurance program. The amount of funding available will depend on state-specific circumstances,” Price wrote.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.